Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder

• 資料種別: 博士論文
• タイトル: Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
• 著者・編者: 伊藤, 秀德
• 著者標目: 伊藤, 秀德
• 出版事項: MDPI
• 出版年月日等: 2023-03-20
• 出版年（W3CDTF）: 2023-03-20
• 並列タイトル等: 過活動膀胱患者におけるミラベグロン投与前後の血圧や脈拍数に対する影響
• タイトル（掲載誌）: Medicina
• 巻号年月日等（掲載誌）: 58 6
• 掲載巻: 58
• 掲載号: 6
• 掲載ページ: 825-
• ISSN（掲載誌）: ISSN : 1648-9144
• 授与機関名: Nagasaki University (長崎大学)
• 授与年月日: 2023-03-20
• 報告番号: 甲医歯薬第1484号
• 学位: 博士(医学)
• 本文の言語コード: eng
• 件名標目: blood pressure; pulse rate; mirabegron; overactive bladder
• 対象利用者: 一般
• 一般注記: 出版タイプ： VoR; Background and Objectives: To determine changes in the blood pressure (BP) and pulse rate (PR) before and after the administration of mirabegron in real-world clinical practice for patients with overactive bladder (OAB). Materials and Methods: This study was conducted in patients newly diagnosed with OAB. Before and 12 weeks after mirabegron treatment, we evaluated the effects on BP and PR. An overall examination was conducted, and the patients were divided into two groups according to their age: a young group (<65 years old) and an old group (≥65 years old). Results: A total of 263 patients were enrolled in this study. In the overall and intragroup comparisons, the systolic BP (SBP) did not change significantly after mirabegron administration. However, an increase in SBP of ≥10 mmHg was observed in 53 (20.2%), 4 (7.4%), and 49 (23.4%) in the entire group, young group, and old group, respectively (p = 0.009). Regarding diastolic BP, a significant decrease after the treatment was detected in entire (71.2 ± 11.4 versus 69.8 ± 10.7 mmHg; p = 0.041) and old patients (71.5 ± 10.6 versus 69.5 ± 10.2 mmHg; p = 0.012). There was no significant change in PR in our study population. Further examination using a propensity match score revealed that age was the risk factor for the increase in SBP after mirabegron administration. Conclusions: Mirabegron does not have any adverse effects on BP and PR. However, since some patients in this study had elevated SBP after administration, we suggest regular BP monitoring during mirabegron treatment.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1484号 学位授与年月日:令和5年3月20日; Author: Hidenori Ito, Tomohiro Matsuo, Kensuke Mitsunari, Kojiro Ohba and Yasuyoshi Miyata; Citation: Medicina, 58(6), art. no. 825; 2022; identifier:Nagasaki University (長崎大学), 博士(医学) (2023-03-20)
• 一次資料へのリンクURL: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27996&item_no=1&attribute_id=70&file_no=1
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• 関連情報: http://hdl.handle.net/10069/00042119
• 関連情報（DOI）: 10.3390/medicina58060825; https://doi.org/10.3390/medicina58060825
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 長崎大学 : 長崎大学学術研究成果リポジトリ